The global ulcerated necrobiosis lipoidica management market is anticipated to attain an impressive valuation of USD 4.4 billion in 2023 and is projected to reach USD 7.9 billion by 2033, trailing a CAGR of 6.03% during the forecast period.
Growing incidences of diabetes as well as shift in urbanization and sedentary lifestyle, are key factors expected to fuel the Ulcerated Necrobiosis Lipoidica Management. Furthermore, improvements in technology in the field of diabetes as well as surging diabetic population is anticipated to propel market growth during the forecast period.
Growing prevalence of risk factors, for example diabetes, cancer, alcoholism, rising geriatric population, surging rate of bacterial infection and growing importance of research on diagnosis and treatment of rare diseases are some major factors that are anticipated to increase the growth and demand of the Global Necrotizing Fasciitis Market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 4.4 billion |
| Anticipated Forecast Value (2033) | USD 7.9 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 6.03% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for Ulcerated Necrobiosis Lipoidica was worth USD 3.5 billion in 2018, while growing at a CAGR of 4.68% during the historical period. Several factors like awareness in wellness and health, the diagnostic and pathology segment are getting a stronghold in the developing countries nowadays which is expected to fuel Ulcerated Necrobiosis Lipoidica treatment market. Moreover, the research and development activities in the field of emerging novel therapeutics is increasing the efficacy of medicine as well as treatment which is presenting growth opportunities for the targeted industry.
On the other hand, selling campaigns started by the global players is propelling the market upwards. Also, increasing focus by government organizations and private agencies such as WHO and pharmaceutical companies to create awareness of necrobiosis Lipoidica will benefit the market in the coming years.
In Addition, PCS499 is an oral emerging drug that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental). It is currently being investigated for the treatment of Ulcerated Necrobiosis Lipoidica. PCS499 and its metabolites work by acting upon multiple pharmacological targets that are important in several conditions. The Food and drug administration granted Orphan Drug Designation for PCS499 for the treatment of necrobiosis lipoidica and seven years of Unites states exclusivity on the FDA approval. Considering these factors and new developments, the revenue growth of Ulcerated Necrobiosis Lipoidica treatment is projected to be worth USD 7.9 billion by end of the forecast period, while exhibiting a CAGR of 6.03%.
Launch of new drugs expected to drive market growth
The increasing demand for effective cure indicated for necrobiosis lipoidica infections as current standard cure for these infections also involves surgical debridgement unfortunately leading to amputations which is expected to fuel market growth. To prevent loss of limb or fatal outcome, the need for novel therapies in Necrobiosis infections rises, which is anticipated to propel market growth during the forecast period. Also rapid discovery of novel therapy like hyperbaric oxygen therapy is further anticipated to augment revenue growth in this market during the forecast period.
Growth in advanced diagnostic techniques for diagnosis of necrobiosis lipoidica such as magnetic resonance imaging is contributing to market expansion of necrobiosis lipoidica treatment market. Furthermore, approval and launch of new medicines by leading companies is the other important factor augmenting growth of this market.
A vast number of drug candidates are in different stages of clinical trials in the United States and Europe. The expected launch and commercialization of these products is anticipated to fuel the global ulcerated necrobiosis lipoidica treatment market during the forecast period. Also, rising healthcare expenditure fuels demand for research and development of biologics and biosimilars for treatment of necrobiosis lipoidica which is expected to propel market growth in the forecast period.
Principal Consultant
High cost and improper diagnosis restraining market expansion
Improver diagnosis of Ulcerated necrobiosis lipoidica disease is anticipated to challenge growth of this market, since initial symptoms are often mistaken for flu. High cost of treatment is also expected to hold back expansion of this market during the projected period.
North America to dominate the market with maximum share
North America is anticipated to dominate the market of Ulcerated necrobiosis lipoidica treatment by accounting for 41% market share by end of the forecast period. The market in this region is projected to be worth more than USD 3.2 billion by 2033. The growth is attributable to increasing prevalence of necrobiosis lipoidica condition in this region. A study was conducted titled “ Development of a new critical pathway for treatment of acute skin structure infections under the clinical development for the drug ‘Dalbavancin’ from the allergen pharmaceutical in the unites states. These developments in this region will open up new opportunities for market expansion of Necrobiosis lipoidica.
On the other hand, an estimated 34.2 million people have diabetes (10.5 % of the United States population. Therefore, the risk of necrobiosis lipoidica diabectorum is anticipated to rise in the region and it will lead to market expansion.
The increasing product pipeline and product approval by regulatory authorities are anticipated to boost the market during the forecast period. For example, in July 2021, the Food and Drug Administration expanded the approval of Dalvance to include treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms in pediatric patients. The treatment was only approved for adults 18 and older few years ago. In addition, in January 2022, Paladin Labs Inc., which is a subsidiary of Endo International plc developed and launched Xydalba (dalbavancin for injection), a 30-minute intravenous therapy in Canada for acute bacterial skin and skin structure infections that can be administered as a single- or two-dose regimen. These factors and developments will lead to market expansion in this region.
Asia Pacific market driving growth with fastest CAGR
The market of ulcerated necrobiosis lipoidica in Asia Pacific is estimated to witness fastest CAGR of 6.5% during the forecast period. This region is anticipated to possess 32.8% market share by end of 2033. Furthermore, market in this region will be worth more than USD 2.59 billion by end of the projected period. The growth in this region is attributed to rising prevalence of acute skin related and skin structure related disorders.
Furthermore, growing awareness, significant rise in healthcare spending and increasing frequency of Necrobiosis Lipoidica Diabeticorum in this region. Moreover, Asia Pacific is an emerging market owing to the increase in point of care approach in health and care. Also, growing number of hospitals in India and China makes a promising market for the treatment market across the globe.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
UVA1 Phototherapy segment driving growth with fastest CAGR
By treatment, UVA1 phototherapy is anticipated to reflect fastest CAGR of 6.8% during the forecast period. This segment is projected to account for 31% market share by end of the projected period. The growth is attributable to better efficacy offered by this therapy and growing prevalence of clinical trials on this method. The treatment by Phototherapy is treated as the first line therapy by the healthcare professionals.
Furthermore, this therapy has been proved to be the most successful therapy than methyl aminolevulinate (MAL)-photodynamic therapy, aminolevulinic acid-PDT, and psoralen plus ultraviolet-A (PUVA) with very less side-effects. Thus, these factors will lead to the fastest growth Ultraviolet A 1 phototherapy for the treatment of ulcerated necrobiosis lipoidica during the forecast period.
Hospitals pushing growth with significant market share
The hospital segment dominated the market of Ulcerated Necrobiosis Lipoidica in 2022, with a market share of 59% . This segment is anticipated to retain its dominance by accounting for more than 71% market share by end of the forecast period. This segment will grow with a CAGR of 5.7% during the projected period. The factors that can be attributed to growth of this segment such as ease of interaction with prescribers and other health professionals are fuelling the demand for this segment.
Start-ups help in understanding the growth opportunities and prospects in any industry. These new businesses have the potential to generate high returns which directly benefits the growth of any industry. These start-ups are naturally more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to volatile market conditions. Some of the start-ups that will augment the expansion of Ulcerated Necrobiosis Lipoidica Management Market are:
The ulcerated necrobiosis lipoidica management market is intensely competitive and consists of numerous key market players. These key players are developing novel delivery systems for treating ulcerated necrobiosis lipoidica. This is estimated to fuel Ulcerated Necrobiosis Lipoidica Management Market. The key players in this market are: Astellas Pharma, Vibcare Pharma, Pfizer, Manus Aktteva Biopharma LLP, Mylan Pharmaceuticals Inc., Upsher-Smith Laboratories, Novartis, Sanofi, Merck, GlaxoSmithKline
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Uulcerated necrobiosis lipoidica management market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 4.4 billion |
| Market Value in 2033 | USD 7.9 billion |
| Growth Rate | CAGR of 6.03 % from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | By treatment, By end-user, By Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, China, Japan, South Korea, Indonesia, Singapore, Thailand, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Astellas Pharma; Vibcare Pharma; Pfizer Inc.; Manus Aktteva Biopharma LLP; Mylan Pharmaceuticals Inc.; Upsher-Smith Laboratories; Novartis AG; Sanofi S.A; Merck & Co. Inc.; GSK Plc. |
| Customization | Available Upon Request |
FMI projects the global Ulcerated Necrobiosis Lipoidica Management Market to expand at 6.03% value CAGR by 2033.
The global Ulcerated Necrobiosis Lipoidica Management Market is expected to garner a market value of USD 7.9 billion by 2033.
FMI has projected North America to be one of the most profitable regions for Ulcerated Necrobiosis Lipoidica Management Market.
Asia Pacific is anticipated to grow fastest during the forecast period.
UVA1 Phototherapy is expected to dominate the market by treatment type during the forecast period
Hospitals are projected to lead the market with maximum share by end of the forecast period
The market value of Ulcerated Necrobiosis Lipoidica Management Market was worth USD 3.5 billion in 2018.
The market in North America is projected to account for 41% market share by end of the forecast period.
1. Executive Summary | Ulcerated Necrobiosis Lipoidica Management Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Skin Grafting 5.2. Photodynamic Therapy 5.3. UVA1 Phototherapy 5.4. Topical Psoralen-UVA Therapy 5.5. Drugs 5.5.1. Antimalarial Agents 5.5.2. Antitubercular Agents 5.5.3. Immunosuppressive Agents 5.5.4. Hemorrheologic Agents 5.5.5. Fumaric Acid Esters 5.5.6. Calcineurin Inhibitors 5.5.7. Corticosteroids 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Specialty Clinics 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Astellas Pharma 15.2. Vibcare Pharma 15.3. Pfizer 15.4. Manus Aktteva Biopharma LLP 15.5. Mylan Pharmaceuticals Inc. 15.6. Upsher-Smith Laboratories 15.7. Novartis 15.8. Sanofi 15.9. Merck 15.10. GlaxoSmithKline 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Ulcerated Necrobiosis Lipoidica Management Market
